Catch the Wind provides update on field trial with Nebraska Public Power District
Posted on: Monday, 26 October 2009, 06:00 CDT
Successful trial results lead to purchase of the Company's Vindicator(R) Laser Wind Sensor"Consistent with our expectations, the Vindicator Laser Wind Sensor's forward wind measurement capabilities were able to improve the alignment of a turbine against the oncoming wind and thus significantly increased power output while reducing equipment stress loads," said
"With our long association with NPPD providing unique measurements of stress loads on their entire fleet of turbines at
As reported previously, Catch the Wind and NPPD agreed to a trial program, which commenced in
Catch the Wind is focused on making wind energy more profitable. The company is commercializing new technology that is designed to improve the performance of a turbine through the effective forward measurement of the wind, resulting in more energy production and reduced maintenance costs.
About Catch the Wind Ltd.
Catch the Wind Ltd. is a high-growth technology company headquartered in
Catch the Wind serves the commercial market sector for laser based wind sensor systems, recognized as the "gold standard" in wind measurement. The company is focused on becoming a major contributor in making clean, renewable wind energy more affordable and profitable. For more information, visit www.catchthewindinc.com.
About SWANtech
SWANtech is a business unit of Curtiss-Wright Flow Control Company, the flow control segment of Curtiss-Wright Corporation (NYSE: CW). SWANtech utilizes its patented Stress Wave Analysis (SWAN(TM)) technology to track operational effects on mechanical equipment, quantify and track wear and to determine the existence of defects and damage. For more information, please visit www.swantech.com
Forward-Looking Information
This news release includes certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed in such forward-looking statements. Forward-looking statements in this news release, include, but are not limited to, economic performance and future plans and objectives of Catch the Wind. Any number of important factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although Catch the Wind believes that the assumptions and factors used in making the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed timeframes or at all. Catch the Wind disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.SOURCE Catch the Wind Ltd.
Source: PR Newswire
Related Articles
- Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
- Health Discovery Corporation Announces Successful Phase II Clinical Trial Results for New Gene-Based Molecular Diagnostic Test for Prostate Cancer
- Health Discovery Corporation Announces Successful Clinical Trial Results for New Molecular Diagnostic Test for Prostate Cancer
- ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
- AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System
- Clinical Trial Shows Device Optimizes Cardiac Resynchronization Therapy in Less Than Two Minutes; St. Jude Medical Announces QuickOpt Optimization Clinical Trial Results and European Regulatory Approvals at Cardiostim 2006
- Spectranetics Announces Publication of LACI Trial Results in Peer-Reviewed Medical Journal
- Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density With Twice-Yearly Dosing
- CEL-SCI Announces Publication of Phase II Cancer Trial Results in Journal of Clinical Oncology
- Nabi Biopharmaceuticals Announces Altastaph(TM) Phase II Trial Results in Neonates
User Comments (0)

RSS Feeds